Reply to the Editor  by Woo, Y. Joseph & Atluri, Pavan
Letters to the EditorBefore cardiopulmonary bypass be-
came widespread, some groups in
Italy2 and the United States3 per-
formed ligation of the ITAs in canine
models and human subjects with is-
chemic heart disease. Reported results
were promising: angina disappeared,
correlating with the disappearance
of ischemic signs at electrocardiogra-
phy. We believe that these data should
be re-explored with the help of
modern technology. Our hypothesis4,5
has been that administration of angio-
genic growth factors combined with
distal occlusion of the ITAs might en-
hance angiogenesis of NCCC.We per-
formed surgical ligature of the ITAs
distally, and vascular endothelial
growth factor was administered into
the occluded arteries. Intuitively, oc-
clusion by means of endovascular em-
bolization is possible as well. It is
known that the ITAs have high plastic
potential, being capable of developing
major branches that work as the only
source of blood in extreme cases of
lower limb ischemia.6 Hence myocar-
dial ischemia should also be able to
stimulate noncoronary collateral blood
flow, preferably diverting this to the
diseased area rather than to the chest
wall.
It will be neither easy nor quick to
demonstrate such theories, but our cur-
rent studies represent a parallel, alter-
native research field, moving in the
same direction of laser transmyocar-
dial revascularization.
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With great interest, we read Piciche`
and associates’ letter entitled, ‘‘Angio-
genesis and surgical or endovascular
enhancement of noncoronary collat-
eral circulation: a new research field.’’
We thank the authors for their kind
comments regarding our article on the
neovasculogenic effects of transmyo-
cardial revascularization. We agree
wholeheartedly with the authors that
in patients with coronary artery dis-
ease, noncoronary collateral circula-
tion and the microvasculature
comprise critical components of myo-
cardial perfusion and viability and
hence greatly affect cardiomyocyte
and ventricular function.Although sur-
gical and percutaneous coronary ther-
apy and investigative research are
focused predominantly on large epicar-
dial coronary vessels, the small collat-Cardiovascular Surgery c June 2010erals and microvasculature are greatly
underappreciated and understudied.
Certainly there are abundant clinical
anecdotes of patients surviving on vari-
ous permutations of coronary and
noncoronary collaterals. Clinicians
have all encountered the patient with
an angiographically absent major coro-
nary artery yetwith the subtendedmyo-
cardium demonstrating completely
normal contractility on echocardio-
graphic analysis. Is such a large region
supplied through coronary collaterals,
noncoronary collaterals from the base
of the heart and posterior pericardial re-
flection or perhaps through the highly
vascularized adhesions that surgeons
encounter when operating on patients
with prior cardiac surgery, renal failure,
or myocardial infarction and Dressler
syndrome? In older patients and in
states of chronic disease, the ability to
generate such collaterals can be im-
paired.1,2 Researchers are beginning to
understand the critical interrelated roles
of endogenous myocardium-mediated
proangiogenic signaling and bone mar-
row–derived endothelial progenitor
cells.3,4 Although initially very promis-
ing, the results of clinical trials aimed at
harnessing this intrinsic revasculariza-
tion machinery have been clinically
equivocal.5-7 Perhaps what is needed
is a refocus on augmenting noncoro-
nary collaterals as an additional driving
force in therapeutic neovascularization.
The authors present a very intrigu-
ing strategy of ligating both distal in-
ternal thoracic arteries to produce
a regional state of hypertension and
hyperperfusion around the mediasti-
num. Coupled with local delivery of
angiogenic cytokines, the authors
propose to enhance the development
of noncoronary collaterals to reper-
fuse the ischemic myocardium in 2
large animal models. The preliminary
background data presented by the au-
thors is encouraging. Although
critics will focus on the preclusion
of a future left internal thoracic ar-
tery–left anterior descending coro-
nary artery graft, the cornerstone of
coronary artery bypass grafting
Letters to the Editorsurgery, the experimental hypothesis
is conceptually exciting and should
be carefully investigated. The au-
thors’ proposal is uniquely novel
and highly innovative, and we cer-
tainly look forward to the findings
with great anticipation.
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